Getting the Most Out of Baculovirus. Linda Lua
|
|
|
- Austin Beasley
- 5 years ago
- Views:
Transcription
1 Getting the Most Out of Baculovirus Linda Lua
2
3 Enabling World Class Research Recombinant Protein Production Discovery, Translational, Preclinical Drug discovery, vaccinology, diagnostics, functional materials, targeting and delivery, therapeutics, bioprocess development, agricultural science Research Training Up-skill professional development Tailored workshops and symposium Consultation
4 Verified Construct Scale-up Expression Protein Purification & Analysis HTP Expression Screening Design & HTP Molecular Cloning A focus of expertise in protein research and a research emphasis on platform technologies
5 Which Way Should I Go?
6 Types of Recombinant Protein Enzymes Glycoproteins Cytokines/interleukins Kinases Transcription factors Structural proteins Membrane proteins Receptors Viral proteins Recombinant peptides
7 Army Malaria Institute
8 International Academic & Industry Brazil Germany New Caledonia New Zealand North America Malaysia Singapore United Kingdom >1000s expression constructs >100s proteins Simple biomolecules to complex multi-protein assemblies Australia 16 Australian universities 11 Government research organizations 13 Companies
9 Baculovirus Technology 1980s Occasional production of difficult to express proteins Rescue projects Technology enhancement Automation High-throughput 2014 A major expression tool in most pharma/biotech labs 50-60% proteins expressed using baculo Vaccines and gene delivery system
10 LOW% HIGH% SPEED% MAMMALIAN% BACULO8INSECT%CELL% YEAST% BACTERIA% CELL8FREE% COST% CELL8FREE% BACTERIA% YEAST% BACULO8INSECT%CELL% MAMMALIAN% TYPICAL%YIELD% CELL8FREE% MAMMALIAN% BACULO8INSECT%CELL% BACTERIA% YEAST% POST% % TRANSLATION% MODIFICATION% BACTERIA% CELL8FREE% YEAST% BACULO8INSECT%CELL% MAMMALIAN% FDA%APPROVAL% CELL8FREE% BACULO8INSECT%CELL% YEAST% BACTERIA% MAMMALIAN%
11 Dengue viral proteins Malaria proteins TB proteins Hendra viral proteins Receptors and ligands Ion channels Kinases Glycoproteins Enzymes Interleukins Hemagglutinin H1, H5, H10 wild-type & mutants Virus-like particles chimeric VLP rbaculovirus 100s recombinant proteins produced in this system Influenza VLP HPV VLP
12 HTP Baculovirus/Insect Cell Platform Cloning 96-well Recombination 24-well Virus amplification 24-deep well 1 week Day 0 Day 7 Expression analysis Expression screening 24-deep well Day 13 Day 10
13 Common Challenges for Secreted Proteins Low expression/secretion Large volume of supernatant Poor target protein recovery and purity Contaminating host proteins
14 Media: Sf900II P3 virus stock MOI 5 TOI hi5-1.5x10 6 cells/ml TOI Sf9-3x10 6 cells/ml
15
16 FlashBACGOLD Bac to Bac HBM gp67 HBM gp67 27 o C 21 o C High Five gp67 Bac to Bac - 21 o C FlashBACGOLD Δv-cath ΔchiA- 27 o C
17 Ni Sepharose Excel Bind-Elute
18 Stability of Virus Stock P3 P4 P5 P6 P7 P8
19 Virus-Like Particle (VLP)
20 Simple to Complex Virus-Like Particles Single layer Multiple layers Non-enveloped Enveloped
21 Expert Rev. Vaccines 9(10), (2010)
22 Enteroviruses Hand Foot and Mouth Disease (HFMD) Poliomyelitis
23 Enterovirus Genome and Viral Structure
24 Enterovirus-like Particles as Vaccines Virus-like particle (VLP) resemble virus Non-infectious as without genetic material Produce using insect cells Co-expression of polyprotein (P1) and protease (for processing of polyprotein into structural proteins) Assembly of structural proteins in VLPs in cells
25 Flow fractionation (AF4) Velocity Size Distribution % MALS, UV & RI Crossflow Process: 1. Sample enters chamber. 2. Crossflow drags particles to membrane 3. Particles diffuse back into flow (rate based on size). Membrane size 4. Smaller particles flow faster than larger particles due to laminar flow. 5. UV, MALS & RI used to determine size distribution
26 Analysis by field-flow fractionationvlps Aggregates Misformed VLPs VLPs Misformed VLPs Chuan et al., Biotech Bioeng 2008 Aggregates
27 Biophysical Characterization TEM analysis: Diameter nm DLS analysis: Diameter - 32 nm 1.2" 110" UV'absorbance'(rela4ve'scale)' 1" 0.8" 0.6" 0.4" Soluble"" Proteins" VLPs" Misformed"" VLPs" 100" 90" 80" 70" 60" 50" 40" 30" Radius'(nm)' 0.2" Aggregates" 20" 10" 0" 0" 0" 10" 20" 30" 40" 50" 60" Time'(min)' AF4 analysis: Diameter - 30 nm
28 Modular VLP Vaccine Design 28 Virus-like particle VP1 Modular VP1 Modular capsomere (5 VP1) Modular VLP (72 capsomeres)
29 Modular VLP Vaccine Design Correct epitope presentation is crucial to induce immune response against target pathogen 2. Module insertion must not disrupt capsomere structure Modular VP1 Computational tools to design and predict modular vaccine candidates, test using insect cells
30 Modular VLP Vaccine Design 30 Virus-like particle VP1 Modular VP1 Modular capsomere (5 VP1) Modular VLP (72 capsomeres)
31 The Future FLU
32 A focus of expertise in protein research and a research emphasis on platform technologies Our track record Our expertise Our capabilities Our platform Chancellor s Award for Team Excellence 2013
33 THANK YOU
New Technology in Vaccine Engineering
Viruses in May Katoomba, August, 2012 New Technology in Vaccine Engineering Anton Middelberg Australian Institute for Bioengineering and Nanotechnology The University of Queensland, Australia Introduction
Oxford Expression Technologies Ltd
Oxford Expression Technologies Ltd Founded in 2007 as a spin out from Oxford Brookes University and Natural Environment Research Council Technology based on the insect baculovirus expression vectors (BEVs)
Bacterial expression of a VLP Sub-unit for rapid and cheap influenza vaccination
Engineering Conferences International ECI Digital Archives Vaccine Technology IV Proceedings Spring 5-23-2012 Bacterial expression of a VLP Sub-unit for rapid and cheap influenza vaccination Anton Middelberg
Overview: Chapter 19 Viruses: A Borrowed Life
Overview: Chapter 19 Viruses: A Borrowed Life Viruses called bacteriophages can infect and set in motion a genetic takeover of bacteria, such as Escherichia coli Viruses lead a kind of borrowed life between
Transforming The Approach to Vaccines and Protein- Based Therapeutics. Alain Doucet, Ph.D. Manager, Process Development, Medicago
Transforming The Approach to Vaccines and Protein- Based Therapeutics Alain Doucet, Ph.D. Manager, Process Development, Medicago 2018-08-15 1 Medicago Overview 2 Novel Technologies 3 Robust Pipeline 2
The humoral immune responses to IBV proteins.
The humoral immune responses to IBV proteins. E. Dan Heller and Rosa Meir The Hebrew University of Jerusalem, Israel COST FA1207 meeting WG2 + WG3, Budapest, Jan. 2015 1 IBV encodes four major structural
A UNIQUE NETWORK OF EXPERTISE DEDICATED TO THE FIGHT AGAINST INFECTIOUS DISEASES
A UNIQUE NETWORK OF EXPERTISE DEDICATED TO THE FIGHT AGAINST INFECTIOUS DISEASES Since 1888, date of its creation, has been committed to contain infectious diseases by working directly in regions where
Zika Virus. It may be devastating, But we might just get one step ahead of it. Learning in Retirement Winter 2017 Daniel Burnside. photo: Newsweek.
Zika Virus It may be devastating, But we might just get one step ahead of it Learning in Retirement Winter 2017 Daniel Burnside photo: Newsweek.com INTRODUCTION TO VIRUSES STRUCTURE GENOME LIFE CYCLE
Viral reproductive cycle
Lecture 29: Viruses Lecture outline 11/11/05 Types of viruses Bacteriophage Lytic and lysogenic life cycles viruses viruses Influenza Prions Mad cow disease 0.5 µm Figure 18.4 Viral structure of capsid
Synthetic Genomics and Its Application to Viral Infectious Diseases. Timothy Stockwell (JCVI) David Wentworth (JCVI)
Synthetic Genomics and Its Application to Viral Infectious Diseases Timothy Stockwell (JCVI) David Wentworth (JCVI) Outline Using informatics to predict drift (strain selection) Synthetic Genomics: Preparedness
numbe r Done by Corrected by Doctor
numbe r 5 Done by Mustafa Khader Corrected by Mahdi Sharawi Doctor Ashraf Khasawneh Viral Replication Mechanisms: (Protein Synthesis) 1. Monocistronic Method: All human cells practice the monocistronic
Foot and Mouth Disease Vaccine Research and Development in India
Foot and Mouth Disease Vaccine Research and Development in India R.Venkataramanan Indian Veterinary Research Institute, Hebbal, Bangalore 560 024 Foot and Mouth Disease in India Present Status Large Susceptible
Biotechnology-Based Vaccines. Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:
Biotechnology-Based Vaccines Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel: 4677363 aalshamsan@ksu.edu.sa Objectives of this lecture By the end of this lecture you will be able to: 1.
QUANTIFICATION RAPID VIRUS WHAT S YOUR APPLICATION?
VIRUS COUNTER 3100 RAPID VIRUS QUANTIFICATION A novel approach for determining Total Virus Particle concentration that provides precise results in minutes, not days. MORE MEANINGFUL RESULTS Get a quantitative
Viral vaccines. Lec. 3 أ.د.فائزة عبد هللا مخلص
Lec. 3 أ.د.فائزة عبد هللا مخلص Viral vaccines 0bjectives 1-Define active immunity. 2-Describe the methods used for the preparation of attenuated live & killed virus vaccines. 3- Comparison of Characteristics
Why chaperone vectors?
Why chaperone vectors? A protein folding initiative An open discussion with structural biologists Protein Structure Initiative: Pilot Phase Whether the pilot phase achieved its goal depends on how we measure
Trends in vaccinology
Trends in vaccinology Mathieu Peeters, MD Joint Conference of European Human Pharmacological Societies and Joint Conference of European Human Pharmacological Societies and 20th Anniversary of AGAH March
Conflict of interest
Helsinki 2012 HPV vaccines for developing countries Lutz Gissmann l.gissmann@dkfz.de Conflict of interest LG is a consultant to GSK and Sanofi Pasteur MSD and, due to existing IP, receives royalties from
DOI: /ICJ poliovirus. [14] (Hand-Foot-Mouth Disease, HFMD) (Herpangina) 71 [26] [17,18,27] 71 picornaviridae
![DOI: /ICJ poliovirus. [14] (Hand-Foot-Mouth Disease, HFMD) (Herpangina) 71 [26] [17,18,27] 71 picornaviridae](/thumbs/93/112612467.jpg "DOI: /ICJ poliovirus. [14] (Hand-Foot-Mouth Disease, HFMD) (Herpangina) 71 [26] [17,18,27] 71 picornaviridae")
174 DOI: 10.6526/ICJ.2016.404 71 71 [14] (Hand-Foot-Mouth Disease, HFMD) (Herpangina) 71 71 picornaviridae poliovirus / 1990 71 [26] [17,18,27] 71 175 [31] ICR NOD/SCID AG129 hpsgl-1 hscarb2 (MP4) (MP4)
J. A. Sands, 21 October 2013 Lehigh University
J. A. Sands, 21 October 2013 Lehigh University Cryptococcus, Candidiasis, Aspergillosis Tuberculosis Cholera Plague Bact. Meningitis Salmonella Listeria Leptospirosis Staph. (MRSA) E. coli Clostridium
VIROLOGY. Engineering Viral Genomes: Retrovirus Vectors
VIROLOGY Engineering Viral Genomes: Retrovirus Vectors Viral vectors Retrovirus replicative cycle Most mammalian retroviruses use trna PRO, trna Lys3, trna Lys1,2 The partially unfolded trna is annealed
An Affordable Pandemic Influenza Vaccine Solution for Developing Countries (and Developed Countries Too)
An Affordable Pandemic Influenza Vaccine Solution for Developing Countries (and Developed Countries Too) James M. Robinson, PE VP Technical and Quality Operations Novavax, Inc. New Cells for New Vaccines
Envelope e_ :------, Envelope glycoproteins e_ ~ Single-stranded RNA ----, Nucleocapsid
Virus Antib(tdies Your Expertise, Our Antibodies, Accelerated Discovery. Envelope e_---------:------, Envelope glycoproteins e_-------1~ Single-stranded RNA ----, Nucleocapsid First identified in 1989,
VACCINE ENGINEERING Dr.T.V.Rao MD
VACCINE ENGINEERING Dr.T.V.Rao MD DR.T.V.RAO MD 1 HISTORICAL PICTURE OF VACCINATION DR.T.V.RAO MD 2 WHAT IS A VACCINE A vaccine is any preparation intended to produce immunity to a disease by stimulating
Human Genome Complexity, Viruses & Genetic Variability
Human Genome Complexity, Viruses & Genetic Variability (Learning Objectives) Learn the types of DNA sequences present in the Human Genome other than genes coding for functional proteins. Review what you
Influenza viruses. Virion. Genome. Genes and proteins. Viruses and hosts. Diseases. Distinctive characteristics
Influenza viruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Virion Enveloped particles, quasi-spherical or filamentous Diameter 80-120 nm Envelope is derived
Fayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES
1 of 7 I. Viral Origin. A. Retrovirus - animal lentiviruses. HIV - BASIC PROPERTIES 1. HIV is a member of the Retrovirus family and more specifically it is a member of the Lentivirus genus of this family.
AP Biology. Viral diseases Polio. Chapter 18. Smallpox. Influenza: 1918 epidemic. Emerging viruses. A sense of size
Hepatitis Viral diseases Polio Chapter 18. Measles Viral Genetics Influenza: 1918 epidemic 30-40 million deaths world-wide Chicken pox Smallpox Eradicated in 1976 vaccinations ceased in 1980 at risk population?
Chapter 18. Viral Genetics. AP Biology
Chapter 18. Viral Genetics 2003-2004 1 A sense of size Comparing eukaryote bacterium virus 2 What is a virus? Is it alive? DNA or RNA enclosed in a protein coat Viruses are not cells Extremely tiny electron
Prophylactic HPV vaccines: next generations
New Trends in Tumor Virology: Annecy Jan 19, 2010 Prophylactic HPV vaccines: next generations Lutz Gissmann l.gissmann@dkfz.de Conflict of interest LG is a consultant to GSK and Sanofi Pasteur MSD and,
7.013 Spring 2005 Problem Set 7
MI Department of Biology 7.013: Introductory Biology - Spring 2005 Instructors: Professor Hazel Sive, Professor yler Jacks, Dr. Claudette Gardel 7.013 Spring 2005 Problem Set 7 FRIDAY May 6th, 2005 Question
Medicago: transforming the approach to vaccines and protein-based therapeutics. Bruce D. Clark PhD President & CEO September 27, 2017
Medicago: transforming the approach to vaccines and protein-based therapeutics Bruce D. Clark PhD President & CEO September 27, 2017 Medicago Overview Focus Manufacturing technology Vaccine technology
Vaccination against Bluetongue
Vaccination against Bluetongue Ivo Claassen Symposium on Bluetongue virus serotype 8, April 19th, Lelystad Vaccination against Bluetongue Introduction Desired characteristics of BT vaccines BT Vaccines
Enhancing the baculovirus expression system with VANKYRIN technology. Kendra Steele, Ph.D.
Enhancing the baculovirus expression system with VANKYRIN technology Kendra Steele, Ph.D. Insect cells Can express mammalian proteins Similarities with mammalian cells Eukaryotic systems How protein are
New technologies for studying human immunity. Lisa Wagar Postdoctoral fellow, Mark Davis lab Stanford University School of Medicine
New technologies for studying human immunity Lisa Wagar Postdoctoral fellow, Mark Davis lab Stanford University School of Medicine New strategies: Human immunology is ideal for a systems approach We have
PREventing EMerging Pathogenic Threats (PREEMPT) Proposers Day
PREventing EMerging Pathogenic Threats (PREEMPT) Proposers Day Dr. Jim Gimlett, Program Manager DARPA Biological Technologies Office (BTO) January 30, 2018 Arlington, VA PREEMPT Agenda Proposers Day Objectives
Influenza virus capture using membrane chromatography: Improving selectivity by matrix design and pseudo-affinity ligand interactions
Engineering Conferences International ECI Digital Archives Vaccine Technology VII Proceedings 6-17-2018 Influenza virus capture using membrane chromatography: Improving selectivity by matrix design and
Viral Antigens Recombinant Proteins. Life Science, Inc. Large Scale Manufacturing, R&D and Custom Services.
Viral Antigens Recombinant Proteins Large Scale Manufacturing, R&D and Custom Services Life Science, Inc. www.meridianlifescience.com Life Science, Inc. Meridian Life Science, (MLS) is an industry leader
Mammalian-type Glycosylation l in LEXSY
Mammalian-type Glycosylation l in LEXSY Case Study: Recombinant hu Erythropoietin Jena Bioscience GmbH Loebstedter Str. 80 07749 Jena, Germany Tel.: +49-3641-628-5000 Fax: +49-3641-628-5100 628 e-mail:
Recombinant Protein Expression Retroviral system
Recombinant Protein Expression Retroviral system Viruses Contains genome DNA or RNA Genome encased in a protein coat or capsid. Some viruses have membrane covering protein coat enveloped virus Ø Essential
Cristina Cassetti, Ph.D.
NIAID Extramural Research Update: Recombinant Influenza Viruses and Biosafety Cristina Cassetti, Ph.D. Influenza Program Officer Division of Microbiology and Infectious Diseases NIAID Influenza virus DMID
WORLD HEALTH ORGANIZATION. Smallpox eradication: destruction of Variola virus stocks
WORLD HEALTH ORGANIZATION EXECUTIVE BOARD EB111/5 111th Session 23 December 2002 Provisional agenda item 5.3 Smallpox eradication: destruction of Variola virus stocks Report by the Secretariat 1. The WHO
PATHOGENS AND DEFENCE AGAINST INFECTIOUS DISEASE. By: Stephanie, Emily, Cem, and Julie
PATHOGENS AND DEFENCE AGAINST INFECTIOUS DISEASE By: Stephanie, Emily, Cem, and Julie Pathogen Pathogen: an organism or virus that causes a disease. Examples: bacteria, fungi, protozoa, virus Disease Cause
5. Influence of multiplicity of infection (MOI) on synchronous baculovirus infections 5.1. Introduction
5. Influence of multiplicity of infection (MOI) on synchronous baculovirus infections 5.1. Introduction The symptoms of baculovirus infection vary greatly between cells in the same cell culture, even if
Antiviral Chemotherapy
12 Antiviral Chemotherapy Why antiviral drugs? Vaccines have provided considerable success in preventing viral diseases; However, they have modest or often no therapeutic effect for individuals who are
Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics
Hepadnaviruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Hepatitis viruses A group of unrelated pathogens termed hepatitis viruses cause the vast majority
VIRUSES. 1. Describe the structure of a virus by completing the following chart.
AP BIOLOGY MOLECULAR GENETICS ACTIVITY #3 NAME DATE HOUR VIRUSES 1. Describe the structure of a virus by completing the following chart. Viral Part Description of Part 2. Some viruses have an envelope
Vaccines: Reaching for higher branches after the low hanging fruit has been picked
Engineering Conferences International ECI Digital Archives Vaccine Technology VI Proceedings 6-12-2016 Vaccines: Reaching for higher branches after the low hanging fruit has been picked Michael G. Kurilla
Lecture 2: Virology. I. Background
Lecture 2: Virology I. Background A. Properties 1. Simple biological systems a. Aggregates of nucleic acids and protein 2. Non-living a. Cannot reproduce or carry out metabolic activities outside of a
18.2 Viruses and Prions
KEY CONCEPT Infections can be caused in several ways. Viruses, bacteria, viroids, and prions can all cause infection. Any disease-causing agent is called a pathogen. 1 nanometer (nm) = one billionth of
ab HRV 3C Protease Inhibitor Screening Kit (Colorimetric)
Version 2 Last updated 2 March 2017 ab211089 HRV 3C Protease Inhibitor Screening Kit (Colorimetric) For the rapid, sensitive and accurate screening of potential HRV 3C Protease inhibitors. This product
Investigation of the genetic differences between bovine herpesvirus type 1 variants and vaccine strains
Investigation of the genetic differences between bovine herpesvirus type 1 variants and vaccine strains Name: Claire Ostertag-Hill Mentor: Dr. Ling Jin Bovine herpesvirus Bovine herpesvirus-1 (BHV-1) Pathogen
SECTION 25-1 REVIEW STRUCTURE. 1. The diameter of viruses ranges from about a. 1 to 2 nm. b. 20 to 250 nm. c. 1 to 2 µm. d. 20 to 250 µm.
SECTION 25-1 REVIEW STRUCTURE VOCABULARY REVIEW Define the following terms. 1. virus 2. capsid 3. retrovirus 4. viroid 5. prion MULTIPLE CHOICE Write the correct letter in the blank. 1. The diameter of
Standards and beyond: challenges of application of old methods to next generation products. Elena Semenova, Penny Post, Tim Fields, Manon Cox
Standards and beyond: challenges of application of old methods to next generation products Elena Semenova, Penny Post, Tim Fields, Manon Cox March 25, 2014 Recombinant Flu vaccines Propagation of the influenza
Page 32 AP Biology: 2013 Exam Review CONCEPT 6 REGULATION
Page 32 AP Biology: 2013 Exam Review CONCEPT 6 REGULATION 1. Feedback a. Negative feedback mechanisms maintain dynamic homeostasis for a particular condition (variable) by regulating physiological processes,
Chapter 08 Lecture Outline
Chapter 08 Lecture Outline See separate PowerPoint slides for all figures and tables preinserted into PowerPoint without notes. Copyright 2016 McGraw-Hill Education. Permission required for reproduction
New prospects for vaccination: from polio to dengue and flu
New prospects for vaccination: from polio to dengue and flu From ancient Chinese variolation to Jenner and cowpox Paul Young Australian Infectious Diseases Research Centre School of Chemistry and Molecular
Service and Collaboration
Summary Section 7 Introduction 68 Exosome and Microvesicle Isolation 69 EV protein quantification, sceening and profiling 69 Nanoparticle Tracking Analysis (NTA) 70 EV Nucleic Acid isolation 70 Nucleic
Product Development for Public Health & Emerging Infections
Product Development for Public Health & Emerging Infections Michael G Kurilla, MD-PhD Director, Office of BioDefense Research Affairs Division of Microbiology & Infectious Diseases Associate Director,
Size nm m m
1 Viral size and organization Size 20-250nm 0.000000002m-0.000000025m Virion structure Capsid Core Acellular obligate intracellular parasites Lack organelles, metabolic activities, and reproduction Replicated
Pharmaceutical. Development of picornavirus-like particle vaccines. Review
Pharmaceutical ac- Development of picornavirus-like particle vaccines Vaccination has been the most effective and economical way of combating the spread of infectious disease. Virus-like particles (VLPs)
Chapter 14 Part One Biotechnology and Industry: Microbes at Work
Chapter 14 Part One Biotechnology and Industry: Microbes at Work Objectives: After reading Chapter 14, you should understand How biotechnology has resulted in numerous pharmaceutical products to help lessen
Ebola virus crisis. Prof. Viktor Volchkov. Molecular basis of viral pathogenicity
Ebola virus crisis Prof. Viktor Volchkov Molecular basis of viral pathogenicity International Centre for Research in Infectiology (CIRI), INSERM Claude Bernard University Lyon-1, Lyon, France viktor.volchkov@inserm.fr
BIT 120. Copy of Cancer/HIV Lecture
BIT 120 Copy of Cancer/HIV Lecture Cancer DEFINITION Any abnormal growth of cells that has malignant potential i.e.. Leukemia Uncontrolled mitosis in WBC Genetic disease caused by an accumulation of mutations
Medical Officer of Health Medical Director, Travel Health and Tropical Medicine Services Winnipeg Regional Health Authority
DNA Vaccines The Future of Travel Health Vaccines? Or Just a Bad Idea? Dr. Pierre J. Plourde Medical Officer of Health Medical Director, Travel Health and Tropical Medicine Services Winnipeg Regional Health
Starting with MICROBIOLOGY
Starting with MICROBIOLOGY Micro means very small and biology is the study of living things. Microbes are the oldest form of life on Earth. They've been here for 3.8 billion years! Microbes live everywhere.
GOVX-B11: A Clade B HIV Vaccine for the Developed World
GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in
Second China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security
Second China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security May 17-19 2017, Wuhan, China Meeting Program Note: Each report will take 25 minutes including
Biology. Slide 1 of 30. End Show. Copyright Pearson Prentice Hall
Biology 1 of 30 2 of 30 What causes disease? 3 of 30 Disease A disease is any change, other than an injury, that disrupts the normal functions of the body. Disease-causing agents are called pathogens.
Our T cell epitope test service offers you:
Our T cell epitope test service offers you: high throughput peptide discovery fast lead-finding maximum of epitopes in a minimum of blood saving effort and costs on developing your own platforms custom-made
Chapter 19: Viruses. 1. Viral Structure & Reproduction. What exactly is a Virus? 11/7/ Viral Structure & Reproduction. 2.
Chapter 19: Viruses 1. Viral Structure & Reproduction 2. Bacteriophages 3. Animal Viruses 4. Viroids & Prions 1. Viral Structure & Reproduction Chapter Reading pp. 393-396 What exactly is a Virus? Viruses
Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses
Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses Weimin Liu University of Alabama at Birmingham Introduction and Rationale Virus-like particles (VLPs)
Picornaviruses. Virion. Genome. Genes and proteins. Viruses and hosts. Diseases. Distinctive characteristics
Picornaviruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Virion Naked icosahedral capsid (T=1) Diameter of 30 nm Genome Linear single-stranded RNA, positive
Chapter 6- An Introduction to Viruses*
Chapter 6- An Introduction to Viruses* *Lecture notes are to be used as a study guide only and do not represent the comprehensive information you will need to know for the exams. 6.1 Overview of Viruses
Chapter 13 Viruses, Viroids, and Prions. Biology 1009 Microbiology Johnson-Summer 2003
Chapter 13 Viruses, Viroids, and Prions Biology 1009 Microbiology Johnson-Summer 2003 Viruses Virology-study of viruses Characteristics: acellular obligate intracellular parasites no ribosomes or means
Coronaviruses. Virion. Genome. Genes and proteins. Viruses and hosts. Diseases. Distinctive characteristics
Coronaviruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Virion Spherical enveloped particles studded with clubbed spikes Diameter 120-160 nm Coiled helical
Discovery of. 1892: Russian biologist Dmitri Ivanovsky publishes. 1931: first images of viruses obtained using
Discovery of (1884: invention of the Chamberland filter with pores smaller than bacteria) 1892: Russian biologist Dmitri Ivanovsky publishes a paper in which shows that extracts from diseased tobacco plants
ab HIV-1 Protease Inhibitor Screening Kit (Fluorometric)
Version 1 Last updated 2 March 2017 ab211106 HIV-1 Protease Inhibitor Screening Kit (Fluorometric) For the rapid, sensitive and accurate screening of potential HIV-1 Protease inhibitors. This product is
PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
BIOL*1090 Introduction To Molecular and Cellular Biology Fall 2014
Last time... BIOL*1090 Introduction To Molecular and Cellular Biology Fall 2014 Lecture 3 - Sept. 15, 2014 Viruses Biological Membranes Karp 7th ed: Chpt. 4; sections 4-1, 4-3 to 4-7 1 2 VIRUS Non-cellular
VIRUSES. Biology Applications Control. David R. Harper. Garland Science Taylor & Francis Group NEW YORK AND LONDON
VIRUSES Biology Applications Control David R. Harper GS Garland Science Taylor & Francis Group NEW YORK AND LONDON vii Chapter 1 Virus Structure and 2.2 VIRUS MORPHOLOGY 26 Infection 1 2.3 VIRAL CLASSIFICATION
Dr. Ahmed K. Ali Attachment and entry of viruses into cells
Lec. 6 Dr. Ahmed K. Ali Attachment and entry of viruses into cells The aim of a virus is to replicate itself, and in order to achieve this aim it needs to enter a host cell, make copies of itself and
Microfluidic Devices for HIV Point-of-Care Diagnostics Xuanhong Cheng
Microfluidic Devices for HIV Point-of-Care Diagnostics Xuanhong Cheng Bioengineering Materials Science and Engineering Lehigh University November 30, 2018 POC Diagnostics Basic Water Supply Microdevices
Development of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine
Development of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine Russell P. Wilson Senior Vice President, Business Development Vaccine World MENA & CIS 2014 Istanbul, Turkey November 19, 2014 1 www.novavax.com
Chapter 19: Viruses. 1. Viral Structure & Reproduction. 2. Bacteriophages. 3. Animal Viruses. 4. Viroids & Prions
Chapter 19: Viruses 1. Viral Structure & Reproduction 2. Bacteriophages 3. Animal Viruses 4. Viroids & Prions 1. Viral Structure & Reproduction Chapter Reading pp. 393-396 What exactly is a Virus? Viruses
OIE Collaborating Centres Reports Activities
OIE Collaborating Centres Reports Activities Activities in 2015 This report has been submitted : 2016-01-16 00:10:12 Title of collaborating centre: Biological Threat Reduction Address of Collaborating
Vaccinology 101 for Fellows
Vaccinology 101 for Fellows Meg Fisher, MD Medical Director, The Children s Hospital Monmouth Medical Center An affiliate of the Saint Barnabas Health Care System Long Branch, NJ Disclosures I have no
Chang Gung University co-commissioned final report. Research Ttitle: Antiviral mechanism study for 254 UVC robot system
co-commissioned final report Research Ttitle: Antiviral mechanism study for 254 UVC robot system Project/Research Number:: Execution duration: 2014.10.16-2015.01.16 Principle Investigator: Professor Shin-Ru
Target Design and Immunogenicity
Target Design and Immunogenicity 03-18-2013 Vidadi Yusibov New Cells, New Vaccines VII: From Protein to Product Vaccine Products Conventional vaccines: Inactivated Live, attenuated Toxoid Recombinant Subunit
All animals have innate immunity, a defense active immediately upon infection Vertebrates also have adaptive immunity
1 2 3 4 5 6 7 8 9 The Immune System All animals have innate immunity, a defense active immediately upon infection Vertebrates also have adaptive immunity Figure 43.2 In innate immunity, recognition and
JEAN-CHRISTOPHE AUDONNET
JEAN-CHRISTOPHE AUDONNET Recombinant Veterinary Vaccines Overview of Progress in the past 30 years and Future Trends Jean-Christophe AUDONNET DVM, Ph.D. Merial R&D OUTLINE OF THE TALK 01 02 ORIGIN AND
Assessment of Influenza Vaccine Production Compatibilities
United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Assessment of Influenza Vaccine Production Compatibilities Joshua Speidel, PhD Influenza
Viral Vectors In The Research Laboratory: Just How Safe Are They? Dawn P. Wooley, Ph.D., SM(NRM), RBP, CBSP
Viral Vectors In The Research Laboratory: Just How Safe Are They? Dawn P. Wooley, Ph.D., SM(NRM), RBP, CBSP 1 Learning Objectives Recognize hazards associated with viral vectors in research and animal
Pathogens and the immune system
Pathogens and the immune system Veronica Leautaud, Ph.D. vl2@ rice.edu Keck Hall 224 / 232-lab Lecture 8 BIOE 301-Bioengineering and World Health Review of lecture 7 Science Science is the human activity
One World One Health: An Economic Perspective
1 One World One Health: An Economic Perspective Beyond Zoonoses: The Threat of Emerging Diseases to Human Security and Conservation, and the Implications for Public Policy James Newcomb Bio Economic Research
the world and viruses
More than 5,450 viruses belonging to more than 2,000 species, 287 genera, 73 families and 3 orders are recognized in the 8th ICTVreport report. the world and viruses 1 1889 H2N2 Emerging viruses in the
answer Marks Guidance 1 (a) 2 max Mark the first answer on each prompt line. ACCEPT ora throughout nucleus / nuclei ; 1 ACCEPT DNA not free
Question answer Marks Guidance 1 (a) max Mark the first answer on each prompt line. ACCEPT ora throughout 1 6 7 nucleus / nuclei ; other named organelle / membrane bound organelles ; linear chromosomes
Dr. Gary Mumaugh. Viruses
Dr. Gary Mumaugh Viruses Viruses in History In 1898, Friedrich Loeffler and Paul Frosch found evidence that the cause of foot-and-mouth disease in livestock was an infectious particle smaller than any